Analyst Price Target is $18.38
▲ +705.92% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Evelo Biosciences in the last 3 months. The average price target is $18.38, with a high forecast of $41.50 and a low forecast of $4.00. The average price target represents a 705.92% upside from the last price of $2.28.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in Evelo Biosciences. This Buy consensus rating has held steady for over two years.
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.